MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Parthenolide

CAS No. : 20554-84-1

MCE 国际站：Parthenolide

产品活性：Parthenolide是在药草短舌匹菊中发现的倍半萜内酯。 Parthenolide通过抑制 NF-κB 活化而表现出抗炎活性; 它还可抑制 HDAC1 蛋白而不影响其他I/II类HDAC。

研究领域：NF-κB | Autophagy | Apoptosis

作用靶点：NF-κB | Autophagy | Mitophagy | Apoptosis

In Vitro: Parthenolide (PTL) has a dose-dependent growth inhibition effect on NSCLC cells Calu-1, H1792, A549, H1299, H157, and H460. Parthenolide can induce cleavage of apoptotic proteins such as CASP8, CASP9, CASP3 and PARP1 both in concentration- and time-dependent manner in tested lung cancer cells, indicating that apoptosis is trigged after Parthenolide exposure. In addition to induction of apoptosis, Parthenolide also induces G₀/G₁ cell cycle arrest in a concentration-dependent manner in A549 cells and G₂/M cell cycle arrest in H1792 cells.

In Vivo: Only Parthenolide, the HDAC inhibitor with anti-inflammatory features, displayed a potent anti-apoptotic effect in Phb1 KO hepatocytes. Indeed, TSA and Parthenolide-treated hepatocytes showed increased levels of FXR, and reduced levels of CYP7A1, HDAC4, TNFα, TRAIL and Bax suggesting a less toxic effect of bile acids as a results of specific HDAC inhibition, resulting in the attenuation of the Phb1 KO hepatocytes apoptotic response. Importantly, Parthenolide exerts a protective effect from the liver injury after BDL in Phb1 KO mice. Indeed, Parthenolide treatment results in a reduction of the mortality rate of this mice after BDL associated with a lower apoptotic response as revealed by a reduction of necrotic areas, Tunel-staining, as well as decreased ALT (8431±957 vs.4225±210 U/L) and AST (4805±300 vs.2242±438 U/L) activities compared to control Phb1 KO mice.

相关产品：Covalent Screening Library Plus | Natural Product Library Plus | Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | NF-κB Signaling Compound Library | Stem Cell Signaling Compound Library | Natural Product Library | Anti-Cancer Compound Library | Clinical Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Antioxidants Compound Library | Differentiation Inducing Compound Library | Oxygen Sensing Compound Library | Anti-COVID-19 Compound Library | Medicine Food Homology Compound Library | Terpenoids Library | Pyroptosis Compound Library | Traditional Chinese Medicine Monomer Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | MG-132 | 3-Methyladenine | LY294002 | Doxorubicin hydrochloride | Bafilomycin A1 | Paclitaxel | Y-27632 dihydrochloride | SB 203580 | Acetylcysteine | Angiotensin II human | Deferoxamine mesylate | SP600125 | 5-Fluorouracil | Staurosporine | Dexamethasone | Bortezomib | Metformin hydrochloride | Tamoxifen | 2-Deoxy-D-glucose | Gemcitabine | U0126-EtOH | Verteporfin | Decitabine | Actinomycin D | Temozolomide | BAY 11⁻⁷082 | Etoposide | Mitomycin C | CCCP

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。